A new clinical trial in the United States is testing an innovative approach that could dramatically reduce the organ shortage crisis. Researchers are experimenting with genetically engineered donor organs that resist rejection, potentially allowing more patients to receive life‑saving transplants. Early results suggest the treatment improves organ viability and lowers the need for lifelong immunosuppression, offering a glimmer of hope for the thousands waiting on transplant lists. The study’s success could reshape transplant protocols and expand access to organs for patients across the country.
